The objective of this study was to explore pretreatment factors predicting LVI status in patients undergoing NAC due to nonmetastatic luminal breast cancer who were ER +/HER2−, which are known to be associated with poorer response to chemotherapy as compared to other molecular subtypes. Here, ESR1 is linked to breast cancer.